Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Vertex Pharmaceuticals (VRTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$509.70 | $600.00 | $325.00 | 2.20% |
Price Target
Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $509.70. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 2.2% from the last closing price of $498.73.
Analyst Price Targets (27)
Broker Rating
Vertex Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.97 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 31 brokerage firms. The current ABR compares to an ABR of 1.87 a month ago based on 30 recommendations.
Of the 31 recommendations deriving the current ABR, 18 are Strong Buy, representing 58.06% of all recommendations. A month ago, Strong Buy represented 63.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 19 | 18 | 19 | 19 | 20 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 10 | 9 | 9 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 1.94 | 1.93 | 1.87 | 1.87 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
10/17/2024 | UBS | Colin N Bristow | Not Available | Strong Buy |
10/16/2024 | Scotiabank | Greg Harrison | Not Available | Hold |
10/10/2024 | Raymond James | Danielle Brill | Not Available | Hold |
10/8/2024 | Cantor Fitzgerald & Co | Olivia Brayer | Strong Buy | Strong Buy |
10/7/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
10/4/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Sell | Strong Sell |
9/19/2024 | Not Identified | Not Identified | Hold | Hold |
8/28/2024 | Evercore Partners | Liisa A Bayko | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Hold |
8/5/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/2/2024 | Guggenheim Securities | Debjit Chattopadhyay | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Hold | Hold |
8/1/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
7/31/2024 | Canaccord Genuity | Whitney Ijem | Strong Sell | Strong Sell |
7/26/2024 | Needham & Company | Joseph R Stringer | Hold | Hold |
7/23/2024 | Cowen & Co. | Philip M Nadeau | Strong Buy | Strong Buy |
7/19/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
7/16/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
6/27/2024 | Atlantic Equities | Steven K Chesney | Not Available | Strong Buy |
6/25/2024 | Maxim Group | Naz Rahman | Hold | Hold |
6/24/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
6/24/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
6/17/2024 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
6/10/2024 | Not Identified | Not Identified | Hold | Hold |
5/31/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
5/7/2024 | Truist Securities | Joon Lee | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.94 |
ABR (Last week) | 1.93 |
# of Recs in ABR | 32 |
Average Target Price | $509.70 |
LT Growth Rate | 13.20% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 87 of 252 |
Current Quarter EPS Est: | 4.13 |
VRTX FAQs
Vertex Pharmaceuticals Incorporated (VRTX) currently has an average brokerage recommendation (ABR) of 1.94 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 32 brokerage firms.
The average price target for Vertex Pharmaceuticals Incorporated (VRTX) is $509.70. The current on short-term price targets is based on 10 reports.
The forecasts for Vertex Pharmaceuticals Incorporated (VRTX) range from a low of $325 to a high of $600. The average price target represents a increase of $5.53 from the last closing price of $483.00.
The current UPSIDE for Vertex Pharmaceuticals Incorporated (VRTX) is 5.53%
Based on short-term price targets offered by 27 analysts, the average price target for Vertex Pharmaceuticals comes to $509.70. The forecasts range from a low of $325.00 to a high of $600.00. The average price target represents an increase of 2.2% from the last closing price of $498.73.